Financials data is unavailable for this security.
View more
Year on year Elite Pharmaceuticals Inc grew revenues 65.79% from 34.16m to 56.63m while net income improved 464.56% from 3.56m to 20.11m.
Gross margin | 44.73% |
---|---|
Net profit margin | -8.98% |
Operating margin | 23.00% |
Return on assets | -8.04% |
---|---|
Return on equity | -13.83% |
Return on investment | -10.06% |
More ▼
Cash flow in USDView more
In 2024, cash reserves at Elite Pharmaceuticals Inc fell by 705.59k. Cash Flow from Financing totalled 3.39m or 5.98% of revenues. In addition the company used 3.28m for operations while cash used for investing totalled 809.65k.
Cash flow per share | -0.0046 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0443 |
---|---|
Tangible book value per share | 0.0375 |
More ▼
Balance sheet in USDView more
Current ratio | 3.52 |
---|---|
Quick ratio | 2.42 |
Total debt/total equity | 0.1953 |
---|---|
Total debt/total capital | 0.1634 |
More ▼